Troglitazone Reduces Plasma Leptin Concentration but Increases Hunger in NIDDM Patients

Abstract

Troglitazone significantly reduces circulating leptin levels at clinical doses. It may affect the eating behavior of poorly controlled NIDDM patients through the improvement of glycemic control and/or the reduction of circulating leptin.